Acura Pharmaceuticals, INC 8-K filings

Acura Pharmaceuticals, Inc. announced a new $200,000 loan from Abuse Deterrent Pharma, LLC, bringing the total outstanding principal to $10,894,279, as the company faces potential operational scaling back or bankruptcy if further financing is not secured by mid-August 2026.

Acura Pharmaceuticals has amended its loan agreement with AD Pharma, extending the principal and interest due date to December 31, 2026, and has also extended the FDA New Drug Application acceptance date for LTX-03 to the same date.

Acura Pharmaceuticals reports new loan agreements totaling $100,000 on multiple dates in March and April 2026, bringing the total principal balance of its secured promissory note to $10,294,279.

Acura Pharmaceuticals has secured additional loans from Abuse Deterrent Pharma, LLC, but warns of potential bankruptcy without further financing by end of January 2026.

Acura Pharmaceuticals has extended critical FDA submission and debt maturity deadlines to June 30, 2026, while securing additional financing from its majority shareholder, Abuse Deterrent Pharma, LLC.

Acura Pharmaceuticals received additional loans from Abuse Deterrent Pharma, LLC, increasing its total debt to $8.99 million, while explicitly warning of potential bankruptcy and complete loss of shareholder value without further financing by early November 2025.

Acura Pharmaceuticals received additional loans from a related party, increasing its debt burden while warning of potential bankruptcy and complete loss of shareholder value without further financing.

Acura Pharmaceuticals, Inc. has secured two new loans totaling $200,000 from its majority shareholder, Abuse Deterrent Pharma, LLC, but warns of potential bankruptcy and complete loss of shareholder value if additional financing is not obtained by early-August 2025.

Acura Pharmaceuticals, Inc. has secured additional loans from its majority shareholder, Abuse Deterrent Pharma, LLC, but warns it faces potential bankruptcy, operational scale-backs, and layoffs by mid-July 2025 without further financing, risking a complete loss of shareholder value.

Acura Pharmaceuticals has extended key debt maturity and FDA submission deadlines to December 31, 2025, while disclosing a precarious financial position requiring immediate additional financing to avoid potential bankruptcy and a complete loss of shareholder value.

Acura Pharmaceuticals and its partner Abuse Deterrent Pharma, LLC, met with the FDA to discuss the development of LTX-03, a hydrocodone and acetaminophen tablet designed with abuse-deterrent properties.

Acura Pharmaceuticals received additional loans from Abuse Deterrent Pharma, LLC, increasing its debt and raising concerns about its ability to continue operations without further financing.

Acura Pharmaceuticals receives additional loans from Abuse Deterrent Pharma, LLC (AD Pharma) and amends agreements to extend the NDA acceptance date for LTX-03 and the maturity date of a secured promissory note, while facing potential operational scaling back if further financing isn't secured.

Acura Pharmaceuticals received a $100,000 loan from Abuse Deterrent Pharma, LLC, increasing their total debt to $7,169,279 plus accrued interest.

Acura Pharmaceuticals received a $50,000 loan from Abuse Deterrent Pharma, LLC, increasing its total debt to approximately $7.44 million, and faces potential operational scale-back if additional financing is not secured by the end of December 2024.

Acura Pharmaceuticals has amended key agreements with Abuse Deterrent Pharma, extending loan maturity and NDA acceptance deadlines, while facing potential operational scaling back if additional funding is not secured.

Acura Pharmaceuticals received a $150,000 loan from Abuse Deterrent Pharma, LLC, increasing their total debt to over $6.5 million, with a looming maturity date and potential operational cutbacks.

Acura Pharmaceuticals received two new loans totaling $250,000 from Abuse Deterrent Pharma, LLC, increasing their total debt to over $6.1 million, with a looming maturity date and potential operational cutbacks.

Acura Pharmaceuticals has received additional loans from Abuse Deterrent Pharma, LLC, extended the NDA acceptance date for LTX-03, and pushed back the maturity date of a secured promissory note, while facing potential operational cutbacks if further funding is not secured.

Acura Pharmaceuticals has announced the retirement of its CFO, Peter A. Clemens, effective September 30, 2024, and the appointment of Robert A. Seiser as his successor, effective August 1, 2024.

Acura Pharmaceuticals received a $200,000 loan from Abuse Deterrent Pharma, LLC, increasing its total debt to $5.6 million, with a looming maturity date and potential operational risks.

Acura Pharmaceuticals has amended agreements with Abuse Deterrent Pharma, extending the FDA acceptance date for a key drug application and the maturity date of a significant promissory note.

Acura Pharmaceuticals received a $250,000 loan from Abuse Deterrent Pharma, LLC, bringing their total debt to $5,419,279, with a looming maturity date of March 31, 2024.

Acura Pharmaceuticals received a $250,000 loan from Abuse Deterrent Pharma, LLC, bringing their total debt to $5.17 million, with a maturity date of March 31, 2024.

Acura Pharmaceuticals has appointed a new independent auditor, Berkowitz, Pollack Brant Advisors + CPAs, after its previous auditor, Cherry Bekaert LLP, terminated their engagement following an acquisition.